NeuroPace Inc(NPCE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.57 | Insider Own | 21.91% | Shs Outstand | 34.3M | Perf Week | -0.99% |
| Market Cap | 0.45B | Forward P/E | - | EPS next Y | 50.97% | Insider Trans | - | Shs Float | 26.8M | Perf Month | -5.45% |
| Enterprise Value | 0.46B | PEG | - | EPS next Q | -0.11 | Inst Own | 76.95% | Short Float | 3.31% | Perf Quarter | 0.93% |
| Income | -0.02B | P/S | 4.52 | EPS this Y | 13.13% | Inst Trans | 2.87% | Short Ratio | 5.75 | Perf Half Y | -22.84% |
| Sales | 0.10B | P/B | 37.53 | EPS next 5Y | 53.56% | ROA | -18.82% | Short Interest | 0.89M | Perf YTD | -15.74% |
| Book/sh | 0.35 | P/C | 8.64 | EPS past 3/5Y | 30.02% 8.43% | ROE | -122.05% | 52W High | -33.62% ($19.60) | Perf Year | 28.43% |
| Cash/sh | 1.51 | P/FCF | - | Sales past 3/5Y | 29.99% 19.44% | ROIC | -24.03% | 52W Low | 41.11% ($9.22) | Perf 3Y | 107.83% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 31.9% | Gross Margin | 79.63% | Volatility(W/M) | 3.5% 4.46% | Perf 5Y | -14.18% |
| Dividend TTM | - | EV/Sales | 4.7 | Sales Y/Y TTM | 11.59% | Oper. Margin | -15.26% | ATR (14) | 0.55 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.91 | EPS Q/Q | 30.93% | Profit Margin | -19.34% | RSI (14) | 47.29 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.94 | Sales Q/Q | -2.95% | SMA20 | 1.25% ($12.85) | Beta | 1.96 | Target Price | $19.78 |
| Payout | - | Debt/Eq | 5.89 | Earnings | 2026/11/12 | SMA50 | -5.13% ($13.71) | Rel Volume | 0.68 | Prev Close | $12.93 |
| Employees | 209 | LT Debt/Eq | 5.7 | EPS/Sales Surpr. | 17.39% 0.94% | SMA200 | -13.29% ($15) | Avg Volume(3M) | 0.15M | Price | $13.01 |
| IPO | 2021/4/22 | Option/Short | Yes/Yes | Trades | 2230 | Volume | 104,579 | Change | 0.62% |
🧠 NeuroPace (NPCE) is a U.S. healthcare company that develops brain-responsive neuromodulation medical devices for patients with drug-resistant focal epilepsy. Its core product, the RNS System, detects real-time brain activity at the seizure focus and delivers personalized stimulation, offering a new treatment alternative for patients whose seizures are difficult to control with existing medications, making it a specialized medical device company.
Over the past 1 year, roughly in the middle
34% below its 1-year high.
Traded less than usual. That is 68% of its average volume.
Next earnings report: November 12
13 days to go.
NPCE has weak earnings and a weak balance sheet
Of every $100 in sales, $15.26 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +13.1% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $452. Peers typically go for $345.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -14.2%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 77.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #62 of 142 in the industry
Based on market cap of $447M.
FAQ
What kind of company is NPCE?
NPCE belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of NPCE?
The market cap of NPCE is approximately $447M, ranking 3,252 within its sector.
What is the 52-week high and low for NPCE?
NPCE has recorded a 52-week high of $19.60 and a low of $9.22.
